Related Experiment Videos
WRYamide, a NPY-based tripeptide that antagonizes feeding in rats
1Department of Surgery, University of Cincinnati Medical Center, 231 Bethesda Avenue, Cincinnati, OH 45267, USA.
Brain Research
|September 5, 1998
Summary
Researchers developed WRYamide, a novel peptide-based NPY antagonist, to combat obesity. This compound effectively reduced feeding behaviors in preclinical models, showing potential for new anti-obesity medications.
Area of Science:
- Neuroendocrinology
- Pharmacology
- Obesity Research
Background:
- Neuropeptide Y (NPY) is a key regulator of feeding behavior.
- Developing effective NPY antagonists is a target for obesity treatment.
Purpose of the Study:
- To investigate the potential of modified NPY peptides as feeding antagonists.
- To evaluate the efficacy of WRYamide, a novel NPY antagonist, in reducing feeding behaviors.
Main Methods:
- Synthesized and tested WRYamide, a low molecular weight peptide antagonist.
- Administered WRYamide via intrahypothalamic and intravenous routes in rodent models.
- Assessed NPY-induced feeding and schedule-induced feeding.
- Evaluated WRYamide's potential as a conditioned taste aversion stimulus.
Main Results:
- WRYamide (N-Ac-Trp-Arg-Tyr-NH2) effectively blocked NPY-induced feeding for 1-4 hours after intrahypothalamic injection.
- Intrahypothalamic WRYamide antagonized schedule-induced feeding for up to 24 hours.
- Intravenous WRYamide significantly reduced schedule-induced feeding for 4 hours.
- WRYamide did not function as a conditioned taste aversion stimulus.
Conclusions:
- WRYamide demonstrates potent anti-feeding effects, acting as an NPY antagonist.
- These findings suggest WRYamide's potential for developing systemically active anti-obesity drugs.